A Bill to set a target for the number of glioblastoma patients who take part in clinical trials each year; to require training for medical oncologists to include training relating to brain cancers; to provide that any drug that has been licensed for use on tumours must be trialled on people with brain tumours; to make provision in relation to neuro-oncology multidisciplinary teams in the NHS, including a requirement that each such team must include a medical oncologist; to require manufacturers of drugs licensed to treat tumours to make those drugs available in specified circumstances for clinical trials relating to brain tumours; and for connected purposes.
House of Commons
Dame Siobhain McDonaghLabour (Co-op)
31 October 2023
The Brain Tumours Bill aims to boost brain cancer care and research. It would set a yearly target for glioblastoma patients to take part in clinical trials, require brain cancer training for medical oncologists, ensure drugs licensed for tumours are trialled on brain tumour patients, require NHS neuro-oncology multidisciplinary teams to include a medical oncologist, and require drug manufacturers to make licensed tumour drugs available for brain tumour trials in specified circumstances.
The bill is at its first reading in the House of Commons. If it progresses, it would move on to further stages such as committee and report stages for scrutiny and potential amendments.
Generated 21 February 2026
The 2022-2023 session of Parliament has prorogued and this Bill will make no further progress.
No recorded votes for this bill yet.
